International Patent:
Title: Dual Antagonist of PGD2/DPr2 and thromboxane A2/TPr receptor and use for the treatment of maladaptive immune response or thrombotic diathesis
International Application No. PCT/IB2021/052693
Filed March 31, 2021
Our PCT comprising claims for use of ramatroban in COVID-19, long COVID, sickle cell disease, Alzheimer's disease, and silicosis.
US Provisional Patents:
Title: Use Of a Dual Receptor Antagonist of Prostaglandin D2/DP2 Receptors and Thromboxane A2/TP Receptors for Prophylaxis and/or Treatment of Tissue Fibrosis in Mammals
US PTO Application #63/092,921
Filed October 16, 2020
Title: Use of ramatroban or other blockers of pgd2/dp2 and/or thromboxane a2 receptor for treatment of diseases and conditions related to infection, vascular injury, inflammation, vasculitis, platelet activation, coagulopathy, and thrombosis
US PTO Application #63/027,751
Filed May 20, 2020
Title: Use Of A CRTH2 Antagonist Such As Ramatroban As A Therapeutic Agent For Treatment Of Adults With Viral Infection Including Covid-19
US PTO Application #63/005,205
Filed April 3, 2020
Title: Use of Ramatroban as a therapeutic agent for prevention and treatment of viral infections including COVID-19
US PTO Application #63/003,286
Filed March 31, 2020